‘Gamechanger’ HIV prevention drug to be made available cheaply in 120 countries
Gilead Sciences says it has signed agreements with six manufacturers to make and sell generic lenacapavir in 120 “high-incidence, resource-limited” countries. Lenacapavir, given as a twice-yearly injection, has shown strong results for HIV prevention. It stopped infection in a trial involving girls and women in South Africa and Uganda, and offered almost complete protection in a second trial that mainly involved men across Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the U.S.
